Chemoimmunotherapy and cellular therapy are the mainstay of the treatment of relapsed/refractory (R/R) lymphomas. Development of resistance and commonly encountered toxicities of these treatments limit their role in achieving desired response rates and durable remissions. The Antibody–Drug Conjugate (ADC) is a novel class of targeted therapy that has demonstrated significant efficacy in treating various cancers, including lymphomas. To date, three ADC agents have been approved for different lymphomas, marking a significant advancement in the field. In this article, we aim to review the concept of ADCs and their application in lymphoma treatment, provide an analysis of currently approved agents, and discuss the ongoing advancements of ADC development.
化学免疫疗法与细胞疗法是复发/难治性淋巴瘤的主要治疗手段。然而，耐药性的产生以及这些疗法常见的毒性反应，限制了其在实现理想缓解率和持久缓解方面的作用。抗体药物偶联物作为一种新型靶向疗法，在包括淋巴瘤在内的多种癌症治疗中展现出显著疗效。目前已有三种抗体药物偶联物获批用于不同亚型淋巴瘤的治疗，标志着该领域的重要进展。本文旨在系统阐述抗体药物偶联物的作用机制及其在淋巴瘤治疗中的应用，分析当前获批药物的临床特征，并探讨该领域的最新研究进展。
Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma
肿瘤(癌症)患者之家